



Lorem ipsum dolor sit amet, consectetur adipiscing elit



Estimado/a {{accTitle}} {{accFname}} {{accLname}},





Orientación y acompañamiento Testing phase 1







Educación en el uso de Nucala (mepolizumab) autoinyector con enfermeras capacitadas.



Material educativo sobre la enfermedad y Nucala (mepolizumab).



**Pacientes de Sistema público o privado con al menos 1 de los siguientes diagnósticos y prescripción:**


-  Asma grave eosinofílica – desde 12 años (100mg cada 4 semanas).
-  Síndrome hipereosinofílico (SHE) – desde 18 años (300mg cada 4 semanas).
-  Granulomatosis eosinofílica con poliangéitis (GEPA) – desde 6 años (300mg, pacientes mayores de 12 años y niños entre 6-12 años, dosis aprobadas según peso: 100-200mg cada 4 semanas).
-  Rinosinusitis crónica con poliposis nasal (RSCcPN) – desde 18 años (100mg cada 4 semanas).

**Consentimiento informado firmado (paciente o representante legal en caso de menores de edad).**



**{{userId}}**  
**{{User.Name}}**  
**Tel {{User.Phone}} Mail {{User.Mail}}**

**How likely are you to recommend this email to others?**





**Most Happy**



**Happy**



**Neutral**



**Sad**



**Very Sad**

Random placeholder text for displaying our services can be found at our portal:  
**[www.exampledomain.com/en-test](#)**  
Further placeholder details about our services are available through our Information Desk at the email address: **[info@example.com](mailto:info@example.com)**.

To report sample incidents or service issues please contact ExampleCorp through the following communication channels phone/email: (00-0) 12345678 option 2 or via email **[support.example@example.com](mailto:support.example@example.com)**. Mailing address: Example Company Ltd.: Main Street 1234 - Floor 5 (Offices 501, 502, and 503), Sample District, Sample City.

This material is not intended to promote any products. Content created by ExampleCorp to be used exclusively as an information resource for the Patient Support Program.  
Informational content designed for specialists qualified to provide consultation and/or treatment services in Sampleland.

Sad **simple** To modify your preferences for receiving sample notifications and/or event alerts, please select the country where you are located:

**Country**

© 2025 is good for me.

About this email: The content contained in this message and any attached files/links is intended solely for certified service providers in Sampleland. If you are not the intended recipient, reading, sharing, copying, or distributing the contents of this message is prohibited and may result in legal action. You are receiving this email because you registered for ExampleCorp's sample updates and/or ExamplePortal services to receive information through this channel at the previously provided email address. To ensure delivery, please add our address to your contact list.

This message was automatically generated from an unmonitored account, and responses to this email will not be saved.

Dummy text lorem: **Country 1**  
Dummy text lorem 2: **Country 2**

The contents of this email are meant only for the specified recipient. Feel free to share this message with others as needed.